
|Videos|February 18, 2016
Dr. Arlene O. Siefker-Radtke on Neoadjuvant Chemotherapy Plus Surgery in Bladder Cancer
Author(s)Arlene O. Siefker-Radtke, MD
Siefker-Radtke says her preferred mathod of neoadjuvant chemotherapy is doxorubicin plus ifosfamide with an alternating regimen of etoposide cisplatin.
Advertisement
Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the pairing of neoadjuvant chemotherapy and surgery in patients with bladder cancer. Siefker-Radtke says her preferred mathod of neoadjuvant chemotherapy is doxorubicin plus ifosfamide with an alternating regimen of etoposide cisplatin.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















